Artificial Intelligence-assisted Primary Care for RSV Prevention (AIPC-RSV) in China

The goal of this clinical trial is to evaluate whether an AI-assisted primary care intervention for parents can increase RSV monoclonal antibody (mAb) uptake among infants, and to assess the cost-effectiveness and potential for implementing the intervention in routine primary care. The main questions it aims to answer are: 1. Does the RSV AI-assisted primary care intervention increase parents' perceived risk of RSV disease, RSV prevention literacy, confidence in using RSV mAb, willingness to use RSV mAb for their infants, and RSV mAb uptake among infants? 2. Is the AI-assisted primary care intervention acceptable, feasible, and potentially sustainable for RSV prevention? 3. Is the AI-assisted primary care intervention cost-effective compared with conventional health education, and what factors may facilitate or hinder its implementation? Researchers will compare parents of infants who receive the RSV AI-assisted primary care intervention with those who do not receive it to determine whether the intervention improves parents' literacy, confidence, and willingness to use RSV mAb and increases RSV mAb uptake among their infants. Participants will: 1. Be recruited and randomly assigned to the intervention group or control group. Participants in the intervention group will have access to an AI assistant for RSV mAb-related health information and get a RSV mAb recommendation from primary care physicians, while participants in the control group will receive routine health education. 2. Complete a survey questionnaire assessing parents' perceived risk of RSV disease, RSV prevention literacy, confidence in using RSV mAb, and willingness to use RSV mAb for their infants. 3. Have their infants' RSV mAb uptake assessed at the end of the trial.